The estimated Net Worth of Anthony Bergmann is at least $326 mil dollars as of 23 October 2023. Mr Bergmann owns over 2,178 units of Capricor Therapeutics Inc stock worth over $9,953 and over the last 10 years he sold CAPR stock worth over $0. In addition, he makes $316,500 as CFO & Corp. Treasurer at Capricor Therapeutics Inc.
Mr has made over 3 trades of the Capricor Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 2,178 units of CAPR stock worth $3,027 on 23 October 2023.
The largest trade he's ever made was exercising 2,178 units of Capricor Therapeutics Inc stock on 23 October 2023 worth over $3,027. On average, Mr trades about 416 units every 185 days since 2015. As of 23 October 2023 he still owns at least 2,381 units of Capricor Therapeutics Inc stock.
You can see the complete history of Mr Bergmann stock trades at the bottom of the page.
Anthony J. Bergmann M.B.A. is the CFO & Corp. Treasurer at Capricor Therapeutics Inc.
As the CFO & Corp. Treasurer of Capricor Therapeutics Inc, the total compensation of Mr A at Capricor Therapeutics Inc is $316,500. There are 1 executives at Capricor Therapeutics Inc getting paid more, with Karen G. Krasney having the highest compensation of $346,750.
Mr A is 35, he's been the CFO & Corp. Treasurer of Capricor Therapeutics Inc since . There are 16 older and 1 younger executives at Capricor Therapeutics Inc. The oldest executive at Capricor Therapeutics Inc is Louis Grasmick, 90, who is the Independent Director.
Anthony's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... y Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: